Arcutis Biotherapeutics, Inc.

NASDAQ:ARQT

Biotechnology

Healthcare
$27.61 -1.93%

-$0.51 today

Market cap
$3.49B
Beta
1.52
P/E (TTM)
-1400.0
EPS (TTM)
-$0.02
52W Low $13.06High $31.77

Volume 0.84M

Average 1.61M

ARQT EBITDA Margin

EBITDA as a percentage of revenue.

Arcutis Biotherapeutics, Inc.NASDAQ: ARQT

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 13.2%

EBITDA Margin was 13.2% in Q2 FY2026, up 27.9 pp from a year earlier. On a trailing-twelve-month basis it was 9.4%, up 35.4 pp year over year. Over 3 fiscal years it widened by 8000.3 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 6 analysts of 19.1% for the fiscal year ending Dec 2026, up from 0.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
13.2%+19.2 pp QoQ
Last fiscal yearDec 2025
0.5%+56.3 pp YoY
LTMJun 2026
9.4%+35.4 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+27.9 pp+13.1 pp-14.7 pp
1 year+56.3 pp+18.7 pp-37.6 pp
3 years+8000.3 pp+49.8 pp-7950.4 pp
5 years+53.2 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
0.5%
Year-over-year change
+56.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ARQT compares with its peers on the latest reported figures

  • ARQT's LTM Jun 2026 EBITDA Margin of 9.4% is the highest of the 4 companies compared; the peer median is -746.2%.
  • Its year-over-year change of +35.4 pp is the 2nd highest of 3, against a peer median of -218.6 pp.
  • Over three fiscal years its change of +8000.3 pp compares with a peer median of -87.4 pp.
ARQT Competitors Peer median
EBITDA Margin for ARQT and competitors
Company Period LTM level YoY 3-year change
ARQTArcutis Biotherapeutics, Inc.LTM Jun 20269.4% +35.4 pp+8000.3 pp
SLGLSol-Gel Technologies Ltd.LTM Mar 2026-10.7% +104.7 pp+365.5 pp
EVMNEvommune, Inc.LTM Mar 2026-746.2% ——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-843.9% -542.0 pp-540.2 pp
TTRXTurn Therapeutics Inc.FY2025— ——
ALDXAldeyra Therapeutics, Inc.FY2025— ——
Peer median (excluding ARQT) -746.2%-218.6 pp-87.4 pp

Competitors are the stored peer set for ARQT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue03.69M59.61M196.54M376.07M
Cost of Revenue763K754K4.99M19.13M36.7M
Gross Profit(763K)2.93M54.62M177.41M339.38M
Gross Margin—79.5%91.6%90.3%90.2%
Research & Development145.56M182.44M110.58M76.42M77.05M
Selling, General & Admin60.97M122.12M185.15M229.39M274.55M
Operating Expenses205.77M304.56M295.72M305.81M351.6M
Depreciation & Amortization454K934K750K2.6M4.67M
EBITDA(205.9M)(294.87M)(228.57M)(109.63M)1.78M
EBITDA Margin—-7999.8%-383.5%-55.8%0.5%
Operating Income(206.53M)(301.63M)(241.1M)(128.4M)(12.23M)
Operating Margin—-8183.0%-404.5%-65.3%-3.3%
Interest Income173K0000
Interest Expense015.65M29.71M27.17M12.08M
Other Income / Expenses173K(9.83M)(17.93M)(11M)(2.74M)
Income Before Tax(206.36M)(311.46M)(259.03M)(139.39M)(14.97M)
Pre-Tax Margin—-8449.8%-434.6%-70.9%-4.0%
Income Tax Expense003.11M647K1.17M
Net Income(206.36M)(311.46M)(262.14M)(140.04M)(16.14M)
Net Margin—-8449.8%-439.8%-71.3%-4.3%
EPS (Basic)(4.17)(5.66)(3.78)(1.16)(0.13)
EPS (Diluted)(4.17)(5.66)(3.78)(1.16)(0.13)
Weighted Avg Shares49.41M55.03M69.31M120.96M127.23M
Weighted Avg Shares (Diluted)49.41M55.03M69.31M120.96M127.23M

Arcutis Biotherapeutics, Inc.

NASDAQ:ARQT

Intrinsic Alpha fair value

Locked

Current Price

$27.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.